TABLE 1

Susceptibility of HCMV strains to artemisone, artesunate, and ganciclovir in different cell culturesb

Cell typeHCMV strainDrug EC50 (μM)a
ArtemisoneArtesunateGanciclovir
HFFAD1691.20 ± 0.4616.98 ± 8.751.36 ± 0.36
TB40/E0.68 ± 0.2819.31 ± 2.040.63 ± 0.39
CI 7040.85 ± 0.1810.791.79
CI 9430.25ND0.40
CI 8931.46ND1.66
MRC-5TB40/E0.22 ± 0.091.53 ± 0.421.67 ± 0.96
ARPE-19TB40/E0.49 ± 0.217.46 ± 2.142.08 ± 0.19
  • a EC50s (the drug concentration resulting in a 50% reduction of viral plaques) were determined by the plaque reduction assay. The results represent those from at least 3 independent experiments and are expressed as means ± standard deviations.

  • b HFF, human foreskin fibroblasts; MRC-5, human fetal lung fibroblasts; ARPE, human retinal pigmented epithelial cells; CI, clinical isolate; ND, not done.